Department of Orthopaedic Surgery, Kaohsiung Chang Gung Memorial Hospital, 123, Ta Pei Road, Niao Sung District, Kaohsiung, Taiwan, Republic of China.
Institute of Public Health, National Yangming University, Taipei, Taiwan, Republic of China.
J Orthop Surg Res. 2018 Jul 11;13(1):173. doi: 10.1186/s13018-018-0883-1.
Venous thromboembolism (VTE) is a serious complication following total joint replacement. The use of rivaroxaban, a highly selective and direct factor Xa inhibitor, has been used widely as a safe and efficacious way to prevent VTE after total joint replacements. However, little is known about the diagnostic efficacy of plasma D-dimer test on deep vein thrombosis (DVT) in patients using rivaroxaban for thromboprophylaxis. The study is aimed to investigate the trend and the diagnostic efficacy of D-dimer test on DVT in patients with primary total knee arthroplasty (TKA) using rivaroxaban for thromboprophylaxis.
Two hundred TKA patients using rivaroxaban postoperatively as chemical prophylaxis were reviewed. D-dimer levels were checked at 4 h after the surgery and on postoperative days 1 and 4. Venography was used to document the presence of DVT. The Mann-Whitney U test was used to detect the differences in the D-dimer levels at different time points in patients with and without DVT, followed by Bonferroni corrections for p values. Receiver operating characteristics (ROC) curves were constructed to determine the best cutoff values of the D-dimer test at each time point after the surgery.
Twenty-nine of the 200 patients were found to have deep vein thrombosis by venography, resulting in an incidence of 14.5%. All patients with DVTs occurred in the distal calf veins, and only one patient was symptomatic. We found significant differences in D-dimer concentration between patients with and without DVT at postoperative day 4. The best cutoff value determined by receiver operating characteristics analysis was 3.8 mg/L at postoperative day 4, with an AUC equal to 63.5%, and a sensitivity, specificity, PPV, and NPV of 58.6, 76, 29.3, and 91.5%, respectively.
Rivaroxaban was effective on reducing DVT in patients undergoing TKA. Because all the DVTs occurred in the leg veins, decreased thrombus volume and size might result in poor accuracy of plasma D-dimer test in prediction or diagnosis of postoperative DVT.
静脉血栓栓塞症(VTE)是全关节置换术后的一种严重并发症。利伐沙班是一种高度选择性和直接的因子 Xa 抑制剂,已被广泛用于预防全关节置换术后的 VTE,被认为是一种安全有效的方法。然而,对于使用利伐沙班进行血栓预防的患者,血浆 D-二聚体试验对深静脉血栓形成(DVT)的诊断效果知之甚少。本研究旨在探讨使用利伐沙班进行血栓预防的原发性全膝关节置换术(TKA)患者中,D-二聚体试验对 DVT 的趋势和诊断效果。
回顾了 200 例使用利伐沙班术后进行化学预防的 TKA 患者。术后 4 小时、术后第 1 天和第 4 天检测 D-二聚体水平。静脉造影术用于记录 DVT 的存在。使用 Mann-Whitney U 检验检测有 DVT 和无 DVT 患者在不同时间点的 D-二聚体水平差异,并对 p 值进行 Bonferroni 校正。绘制术后每个时间点的 D-二聚体试验的最佳截断值的受试者工作特征(ROC)曲线。
200 例患者中有 29 例经静脉造影术发现深静脉血栓形成,发生率为 14.5%。所有 DVT 均发生在小腿远端静脉,仅有 1 例患者有症状。我们发现术后第 4 天有 DVT 和无 DVT 的患者 D-二聚体浓度有显著差异。ROC 分析确定的最佳截断值为术后第 4 天的 3.8mg/L,AUC 等于 63.5%,灵敏度、特异性、PPV 和 NPV 分别为 58.6%、76%、29.3%和 91.5%。
利伐沙班可有效减少 TKA 患者的 DVT。由于所有 DVT 均发生在腿部静脉,血栓体积和大小的减少可能导致血浆 D-二聚体试验对术后 DVT 的预测或诊断准确性较差。